ATP合酶β亚基功能与疾病

doi:10.12092/j.issn.1009-2501.2018.04.017

摘要/Abstract

摘要：

ATP合酶，又称F1F0-ATP合成酶，是位于线粒体内膜、叶绿体类囊体膜和光合菌质膜上的参与呼吸链氧化磷酸化的最后环节。其结构包含F1和F0两个亚单位，共同作用于ATP的分解和合成。ATP合酶β亚基是F1F0-ATP合成酶F1亚单位的重要组件，该亚基包含ATP合成和水解所需的催化位点，其功能好坏与疾病发生直接相关。本文就ATP合酶β亚基功能与糖尿病、肿瘤、肥胖症等疾病的关系作一综述。

关键词: ATP合酶β亚基, 旋转催化, 糖尿病, 肿瘤, 肥胖

Abstract:

ATP synthase, also known as F1F0-ATP synthase, is the last link in the oxidative phosphorylation of respiratory chain in the mitochondrial membrane, chloroplast thylakoid membranes and photosynthetic bacteria membrane. The structure contains two subunits of F1 and F0, which are combined to decompose and synthesize ATP. ATP synthase beta subunit is an important component of F1F0-ATP synthase F1 subunit, which contains the catalytic sites needed for ATP synthesis and hydrolysis, and its function is directly related to the occurrence of disease. This article reviews the relationship between ATP synthase beta subunit and diabetes, tumor, obesity and other diseases.

Key words: ATP synthase beta subunit, rotational catalysis, diabetes, tumor, obesity

中图分类号:

R963

袁李佳龙，秦旭平. ATP合酶β亚基功能与疾病[J]. 中国临床药理学与治疗学, 2018, 23(4): 464-470.

YUAN Lijialong, QIN Xuping. ATP synthase beta subunit function and disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 464-470.

参考文献

［1］Xu T, Pagadala V, Mueller DM, et al. Understanding structure, function, and mutations in the mitochondrial ATP synthase［J］. Microb Cell, 2015, 2(4):105-125.
［2］Junge W, Nelson N. ATP Synthase［J］. Annu Rev Biochem, 2015, 84:631-657.
［3］Feniouk BA, Suzuki T, Yoshida M.The role of subunit epsilon in the catalysis and regulation of FOF1-ATP synthase［J］. Biochim Biophys Acta, 2006, 1757(5/6):326-338.
［4］Mnatsakanyan N, Kemboi SK, Salas J, et al.The beta subunit loop that couples catalysis and rotation in ATP synthase has a critical length［J］. J Biol Chem ,2011, 286(34):29788-29796.
［5］Watanabe R, Koyasu K, You H, et al.Torque transmission mechanism via DELSEED loop of F1-ATPase［J］. Biophys J, 2015, 108(5):1144-1152.
［6］Seo H, Lee I, Chung HS, et al.ATP5B regulates mitochondrial fission and fusion in mammalian cells［J］. Anim Cells Syst, 2016, 20(3):157-164.
［7］Ito Y, Ikeguchi M. Mechanism of the alphabeta conformational change in F1-ATPase after ATP hydrolysis: freeenergy simulations［J］. Biophys J,2015, 108(1):85-97.
［8］Kikuchi Y, Naka Y, Osakabe H, et al. Thermodynamic analyses of nucleotide binding to an isolated monomeric beta subunit and the alpha3beta3gamma subcomplex of F1-ATPase［J］. Biophys J, 2013, 105(11):2541-2548.
［9］La T, ClarkWalker GD, Wang X, et al. Mutations on the N-terminal edge of the DELSEED loop in either the alpha or beta subunit of the mitochondrial F1-ATPase enhance ATP hydrolysis in the absence of the central gamma rotor［J］. Eukaryot Cell, 2013, 12(11):1451-1461.
［10］GarciaBermudez J, Cuezva JM. The ATPase Inhibitory Factor 1 (IF1): A master regulator of energy metabolism and of cell survival［J］. Biochim Biophys Acta, 2016, 1857(8):1167-1182.
［11］Bisetto E, Comelli M, Salzano AM, et al.Proteomic analysis of F1F0-ATP synthase super-assembly in mitochondria of cardiomyoblasts undergoing differentiation to the cardiac lineage［J］. Biochim Biophys Acta, 2013, 1827(7):807-816.
［12］Jonckheere AI, Renkema GH, Bras M, et al. A complex V ATP5A1 defect causes fatal neonatal mitochondrial encephalopathy［J］. Brain, 2013, 136(Pt 5):1544-1554.
［13］Mayr JA, Havlickova V, Zimmermann F, et al. Mitochondrial ATP synthase deficiency due to a mutation in the ATP5E gene for the F1 epsilon subunit［J］. Hum Mol Genet, 2010, 19(17):3430-3439.
［14］Engelen-Lee J, Blokhuis AM, Spliet WGM, et al. Proteomic profiling of the spinal cord in ALS: decreased ATP5D levels suggest synaptic dysfunction in ALS pathogenesis［J］. Amyotroph Lateral Scler Frontotemporal Degener, 2017, 18(3/4):210-220.
［15］Hojlund K, Wrzesinski K, Larsen PM, et al.Proteome analysis reveals phosphorylation of ATP synthase betasubunit in human skeletal muscle and proteins with potential roles in type 2 diabetes［J］. J Biol Chem, 2003, 278(12):10436-10442.
［16］Guan SS, Sheu ML, Wu CT, et al. ATP synthase subunit-beta down-regulation aggravates diabetic nephropathy［J］. Sci Rep, 2015, 5:14561.
［17］Wang C, Chen Z, Li S, Zhang Y, Jia S, Li J, Chi Y, Miao Y, Guan Y, Yang J: Hepatic overexpression of ATP synthase beta subunit activates PI3K/Akt pathway to ameliorate hyperglycemia of diabetic mice［J］. Diabetes,2014, 63(3):947-959.
［18］Hojlund K, Yi Z, Lefort N, et al. Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulinresistant muscle［J］. Diabetologia, 2010, 53(3):541-551.
［19］Tran L, Hanavan PD, Campbell LE, et al.Prolonged Exposure of Primary Human Muscle Cells to Plasma Fatty Acids Associated with Obese Phenotype Induces Persistent Suppression of Muscle Mitochondrial ATP Synthase beta Subunit［J］. PLoS One, 2016, 11(8):e0160057.
［20］Howard AD, Verghese PB, Arrese EL, et al.The betasubunit of ATP synthase is involved in cellular uptake and resecretion of apoA-I but does not control apoA-I-induced lipid efflux in adipocytes［J］. Mol Cell Biochem, 2011, 348(1-2):155-164.
［21］Song K, Han Y, Zhang L, et al. ATP Synthase beta-Chain Overexpression in SR-BI Knockout Mice Increases HDL Uptake and Reduces Plasma HDL Level［J］. Int J Endocrinol, 2014, 2014:356432.
［22］Huebbers CU, Adam AC, Preuss SF, et al.High glucose uptake unexpectedly is accompanied by high levels of the mitochondrial ss-F1-ATPase subunit in head and neck squamous cell carcinoma［J］. Oncotarget, 2015, 6(34):36172-36184.
［23］郑鑫.ATP5B参与人肝海绵状血管瘤形成［D］. 华中科技大学, 2013.
［24］Fliedner SM, Yang C, Thompson E, et al.Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells［J］. Am J Cancer Res, 2015, 5(4):1558-1570.
［25］Li W, Li Y, Li G, et al.Ectopic expression of the ATP synthase beta subunit on the membrane of PC-3M cells supports its potential role in prostate cancer metastasis［J］. Int J Oncol, 2017, 50(4):1312-1320.
［26］Chi SL, Wahl ML, Mowery YM, et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase［J］. Cancer Res, 2007, 67(10):4716-4724.
［27］WenLi Z, Jian W, Yan-Fang T, et al. Inhibition of the ecto-beta subunit of F1F0-ATPase inhibits proliferation and induces apoptosis in acute myeloid leukemia cell lines［J］. J Exp Clin Cancer Res, 2012, 31:92.
［28］张艳.ATP5B基因对宫颈癌HeLa细胞生物学功能的影响［D］. 天津医科大学, 2010.
［29］Xiao X, Yang J, Li R, et al.Deregulation of mitochondrial ATPsyn-beta in acute myeloid leukemia cells and with increased drug resistance［J/OL］. PLoS One, 2013, 8(12):e83610.
［30］Bruggemann M, Gromes A, Poss M, et al. Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma［J］. Transl Oncol, 2017, 10(4):661-668.
［31］Shin S, Kim KS. Human brain endothelial ATP synthase beta-subunit is mannose-insensitive binding target of FimH［J］. FEMS Microbiol Lett, 2010, 303(2):156-162.
［32］Nann D, Berg CP, Preuss BE, et al. Analysis of the clinical relevance of antimitochondrial antibodies to the beta-and gamma-subunits of the F1F0-ATPase in patients with primary biliary cirrhosis［J］. BMC Gastroenterol, 2012, 12:152.
［33］李赛姣, 周丹妮,尹太郎,等.ATP合成酶β亚单位在PCOS伴2型糖尿病大鼠胰岛中的表达［J］. 生殖医学杂志, 2017, 26(1):64-69.
［34］Xie XY,Han CF,Zeng WQ, et al.Possible Involvement of F1F0-ATP synthase and Intracellular ATP in Keratinocyte Differentiation in normal skin and skin lesions［J］. Sci Rep, 2017, 7:42672.
［35］Zuo J, Lei M, Wen M, et al. Overexpression of ATP5b promotes cell proliferation in asthma［J］. Mol Med Rep, 2017, 16(5):6946-6952.
［36］Zhang X, Ren X, Zhang Q, et al. PGC-1alpha/ERRalpha-Sirt3 Pathway Regulates DAergic Neuronal Death by Directly Deacetylating SOD2 and ATP Synthase beta［J］. Antioxid Redox Signal, 2016, 24(6):312-328.
［37］Whitaker RM, Korrapati MC, Stallons LJ, et al.Urinary ATP synthase subunit beta Is a novel biomarker of renal mitochondrial dysfunction in acute kidney injury［J］. Toxicol Sci, 2015, 145(1):108-117.
［38］Zhao Q, Yang Y, Wang CL, et al. ATP5B and ETFB metabolic markers in children with congenital hydronephrosis［J］. Mol Med Rep 2016, 14(6):5111-5115.
［39］段美艳. ATP5B基因启动子活性分析与组织差异性表达研究［D］.西北农林科技大学, 2014.
［40］Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis［J］. Science,2005,307(5707):223-227.
［41］Blatt NB, Bednarski JJ, Warner RE, et al.Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility［J］. J Clin Invest,2002,110(8):1123-1132.
［42］Gledhill JR, Montgomery MG, Leslie AG, et al.Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols［J］. Proc Natl Acad Sci U S A, 2007, 104(34):13632-13637.
［43］Huang TC, Chang HY, Hsu CH, et al. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B［J］. J Proteome Res,2008, 7(4):1433-1444.
［44］Grover GJ, Atwal KS, Sleph PG, et al. Excessive ATP hydrolysis in ischemic myocardium by mitochondrial F1F0ATPase: effect of selective pharmacological inhibition of mitochondrial ATPase hydrolase activity［J］. Am J Physiol Heart Circ Physiol, 2004, 287(4):H1747-1755.
［45］张成. 抗ATP5B单克隆抗体制备及其性质研究［D］. 福建农林大学, 2011.
［46］Yuan J, Zhang C, Fang S, et al. A monoclonal antibody against F1-F0 ATP synthase beta subunit［J］. Hybridoma (Larchmt), 2012, 31(5):352-357.
［47］郑书琪. microRNA101通过靶定ATP5B调控HSV-1的复制［D］. 天津医科大学, 2011.
［48］韩旭. 白藜芦醇对人髓母细胞瘤细胞中GRP78、ATP5B和VEGF的表达影响及其潜在生物学意义分析［D］. 大连医科大学, 2015.
［49］Huang S, Wang J, Cui Y. 2,2',4,4'-Tetrabromodiphenyl ether injures cell viability and mitochondrial function of mouse spermatocytes by decreasing mitochondrial proteins Atp5b and Uqcrc1［J］. Environ Toxicol Pharmacol, 2016, 46:301-310.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[3]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[4]	李坤, 李璐璐, 李楠楠, 胡卫红, 周建超. 成人肾移植术后血糖控制和CYP3A5基因多态性对他克莫司谷浓度的影响[J]. 中国临床药理学与治疗学, 2023, 28(7): 767-774.
[5]	李艳阳, 王云姣, 吕仕超. 中药注射液防治抗肿瘤药物心脏毒性的效应和机制[J]. 中国临床药理学与治疗学, 2023, 28(5): 572-577.
[6]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[7]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[8]	王思宇, 李佳蔚, 李程豪, 李玲, 郭晴阳, 邱璐, 周世琴, 刘永琦. 乳酸脱氢酶A在消化系统肿瘤中的作用及相关药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 445-454.
[9]	张雪娇, 刘洁婷, 李鲁新, 陈培剑, 丁明璐, 孙梦伟, 初彦辉, 张珍. 达格列净对1型糖尿病小鼠心肌损伤的影响及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 257-265.
[10]	李珊, 柳熠鑫, 任菲菲, 李相晨, 张志清. 天然植物活性成分通过下调 P-糖蛋白逆转肿瘤多药耐药的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 331-340.
[11]	郭怡洵, 关晓印, 王博, 魏英达, 张岩, 林建华. 肌少性肥胖的发病机制及潜在治疗靶点研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 341-346.
[12]	白佳, 杨虹, 李玲玲, 张洋洋, 杨莹, 吕海宏. 维生素D通过线粒体/自噬途径影响糖尿病神经病变机制的研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 214-219.
[13]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[14]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[15]	马怡彤, 马建红, 高亚婷, 刘畅. 脂肪细胞因子在子宫内膜癌中的作用及研究进展[J]. 中国临床药理学与治疗学, 2023, 28(11): 1315-1320.